Is there an association between vitamin D and liver fibrosis in patients with chronic hepatitis C?

Kalinca da Silva OLIVEIRA1, Caroline BUSS1,2 and Cristiane Valle TOVO1,3

ABSTRACT – Background – Vitamin D is known for its immunomodulatory, anti-inflammatory and antifibrotic properties, which are quite relevant in the pathogenesis and treatment of many causes of chronic liver disease. Objective – This study aimed to evaluate the association between serum vitamin D levels and the histopathological findings in patients with chronic hepatitis C virus infection. Methods – Cross-sectional study composed of patients with chronic hepatitis C. All patients underwent vitamin D 25 dosage and anthropometric data analysis. Liver biopsy was performed in a maximum 36-month period before inclusion in the study. Results – Of the 74 patients included in the study, 45 (60.8%) were women, mean age was 57.03±9.24 years, and 63 (85.1%) were white. No association was observed between the serum levels of vitamin D and inflammatory activity (P=0.699) nor with the degree of liver fibrosis (P=0.269). Conclusion – In this study, no association was observed between vitamin D and inflammatory activity, as well as the degree of liver fibrosis, in patients with chronic hepatitis C.

INTRODUCTION

Vitamin D has immunomodulatory, anti-inflammatory and antifibrotic properties, which are relevant in the treatment of many causes of chronic liver disease(12). Vitamin D deficiency has been observed in most patients with chronic liver disease(1,7), regardless of the liver disease etiology(16,22). An inversely proportional relationship has been described between vitamin D serum levels and liver fibrosis and response to antiviral treatment with interferon and ribavirin, as well(20).

METHODS

A cross-sectional study was developed in a convenience sample composed of patients with chronic HCV infection, with or without cirrhosis, between July 2012 and May 2013.

Seventy-four patients were consecutively included, considering the following: age 18 and over, chronic HCV infection, defined by positive anti-HCV serological test and confirmation of viremia by RNA-HCV. All patients underwent liver biopsy in a maximum 36-month period prior to the inclusion in the study. Patients must not have been under HCV treatment.

Patients with current or previous alcohol abuse problems (80g/day)(19) and coinfected by the hepatitis B (HBV) and/or human immunodeficiency viruses (HIV) were excluded from the study.

No patients were under vitamin D supplementation in the present or in the past. Vitamin D 25 serum concentration was evaluated in all patients by electrochemiluminescence method, using Roche Diagnostics Elecsys analyzer (Switzerland). To evaluate the vitamin D levels, the cutoff was established according to the Endocrine Society Clinical Practice Guideline: deficiency ≤20 ng/mL; insufficiency 21-29 ng/mL and sufficiency ≥30 ng/mL(11).

Age was analyzed using percentiles (p25∕p50∕p75). The following anthropometric data were evaluated: weight, height and body mass index (BMI), calculated by the formula weight/height²(25).

Patients were not under nutritional monitoring.

Anti-HCV antibodies were detected by ELISA III test, in accordance with manufacturing instructions (Abbott Axsym System, N. Chicago/IL, EUA), followed by real-time polymerase chain reaction (PCR).

Liver biopsy was performed as part of the clinical evaluation protocol to assess HCV treatment indication, using Metavir score(3) for staging. The presence of cirrhosis was evaluated by clinical laboratory methods, image and histopathological analysis, whenever necessary.

This research was submitted and approved by the local Ethics Committee (number 3676/11) and presents minimum risk to the patients. All patients signed the Informed Consent in order to take part in the study.
DISCUSSION

No association between the vitamin D serum levels and the different degrees of inflammatory activity or liver fibrosis was found in this study. Some studies examined the relationship between the vitamin D serum level and the progression of the disease in patients with chronic hepatitis C(5,10,12), but this is a controversial issue.

It has been suggested that HCV reduces the production of 7-dehydrocholesterol, the precursor of endogenous vitamin D. Most patients presented low vitamin D levels, suggesting that HCV depresses serum levels and changes the lipid metabolism(10).

Vitamin D deficiency is closely related to the severity of some chronic liver diseases(1,2,7,17,20). Vitamin D anti-inflammatory and modulating properties could impact on disease progression especially on HCV chronic liver disease(20). Some authors observed that vitamin D might have an impact on other outcomes and in the response to the treatment of patients with chronic hepatitis C(9,18,21,26).

In the present study, 9 (12.2%) patients presented was observed deficiency. Similar results have been shown in the literature(9) in the population with HCV, although some reports present a high index of vitamin D deficiency/insufficiency.

A recent study(9) showed an inverse relationship between vitamin D levels and viral load, liver fibrosis and treatment outcomes, supporting the hypothesis that the improvement of vitamin D status may have considerable potential to amend the host defense against HCV infection and response to therapy.

An independent association between low vitamin D serum levels and greater degree of inflammatory activity has been suggested(1,13).

A probable explanation for the association between lower vitamin D levels and lower inflammatory activity in the liver would be the decrease of 25-hydroxylase activity, promoting decrease in vitamin D hydroxylation activity and, hence, lower serum levels(13). However, this association was not observed in this study, corroborating Petta et al.’s findings(9), putting in question this potential mechanism.

Some studies show that vitamin D serum levels are inversely related to liver fibrosis, showing a relationship between the anti-inflammatory effects(10,14,20). Thus, vitamin D deficiency could contribute to a

TABLE 1. Mean vitamin D serum levels versus liver biopsy according the Metavir score (N=74)

<table>
<thead>
<tr>
<th>Variables</th>
<th>N(%)</th>
<th>Sufficiency</th>
<th>Insufficiency</th>
<th>Deficiency</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Inflammatory activity</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Absent</td>
<td>12 (16.2)</td>
<td>7 (14.6%)</td>
<td>4 (23.5%)</td>
<td>1 (11.1%)</td>
<td>0.699</td>
</tr>
<tr>
<td>Minimum</td>
<td>24 (32.4)</td>
<td>14 (29.2%)</td>
<td>6 (35.3%)</td>
<td>4 (44.4%)</td>
<td></td>
</tr>
<tr>
<td>Mild</td>
<td>33 (44.6)</td>
<td>24 (50.0%)</td>
<td>5 (29.4%)</td>
<td>4 (44.4%)</td>
<td></td>
</tr>
<tr>
<td>Severe</td>
<td>5 (6.8)</td>
<td>3 (6.3%)</td>
<td>2 (11.8%)</td>
<td>0 (0.0%)</td>
<td></td>
</tr>
<tr>
<td><strong>Degree of fibrosis</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.269</td>
</tr>
<tr>
<td>Absence of fibrosis</td>
<td>5 (6.8)</td>
<td>3 (6.3%)</td>
<td>1 (5.9%)</td>
<td>1 (11.1%)</td>
<td></td>
</tr>
<tr>
<td>Portal without septa</td>
<td>12 (16.2)</td>
<td>7 (14.6%)</td>
<td>5 (29.4%)</td>
<td>0 (0.0%)</td>
<td></td>
</tr>
<tr>
<td>Portal with rare septa</td>
<td>21 (28.4)</td>
<td>17 (35.4%)</td>
<td>3 (17.6%)</td>
<td>1 (11.1%)</td>
<td></td>
</tr>
<tr>
<td>Portal with numerous septa</td>
<td>15 (20.3)</td>
<td>9 (18.8%)</td>
<td>2 (11.8%)</td>
<td>4 (44.4%)</td>
<td></td>
</tr>
<tr>
<td>Cirrhosis</td>
<td>21 (28.4)</td>
<td>12 (25.0%)</td>
<td>6 (35.3%)</td>
<td>3 (33.3%)</td>
<td></td>
</tr>
</tbody>
</table>

* ng/mL: nanograms per milliliter. ** Metavir score.

RESUMO – Contexto – A vitamina D é conhecida por possuir propriedades imunomoduladoras, anti-inflamatórias e antifibróticas, relevantes na patogênese e tratamento de muitas causas de doença hepática crônica. Objetivo – Este estudo tem como objetivo avaliar a associação entre os níveis séricos de vitamina D e os achados histopatológicos em pacientes com infecção crônica do vírus da hepatite C. Métodos – Estudo transversal, composto por pacientes com hepatite C crônica. Todos os pacientes foram submetidos à dosagem de vitamina D e análise de dados antropométricos. A biópsia hepática foi realizada em um período máximo de 36 meses antes da inclusão no estudo. Resultados – Dos 74 pacientes incluídos no estudo, 45 (60,8%) eram mulheres, média de idade de 57,03±9,24 anos e 63 (85,1%) eram brancos. Não foi observada associação entre os níveis séricos de vitamina D e atividade inflamatória (P=0,699), nem com o grau de fibrose hepática (P=0,269). Conclusão – No presente estudo, não foi observada associação entre a vitamina D e a atividade inflamatória, bem como com o grau de fibrose hepática, em pacientes com hepatite C crônica.


REFERENCES